Our goal is the improved diagnosis and treatment of patients with hemostatic defects, and so we have been studying normal and abnormal hemostasis. The interaction of the platelet and the blood vessel is being investigated in pigs with von Willebrand's disease. The production of von Willebrand factor and its interaction with the platelet is being studied in endothelial cell cultures. The structure and function of purified von Willebrand factor is being investigated and the role of this material in hemostasis by in vivo and in vitro techniques including interaction of platelets with artificial surfaces. The investigation of the Willebrand factor molecule is being extended by attempts to purify and characterize factor VIII coagulant activity. Pigs with von Willebrand's disease appear to be resistant to the development of atherosclerosis, and the role of the platelet in atherosclerosis is being investigated. The platelet is also being studied as the initiator of intrinsic coagulation. Normal coagulation involves the activation of prothrombin which is being studied in purified systems and by measuring the turnover of the activation products in dogs. Immunologic probes are being used to investigate the activation products of prothrombin (including thrombin) and other coagulation factors such as factor V. In conjunction with the platelet studies, the regulation of coagulation by circulating inhibitors is being investigated including the role of platelet factor 4 and heparin. The investigation of normal and abnormal hemostasis is designed to give greater insight into the normal control of hemostasis and how symptoms arise and laboratory tests become abnormal when the control is imperfect.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL017430-12
Application #
3097595
Study Section
Heart, Lung, and Blood Research Review Committee B (HLBB)
Project Start
1974-09-01
Project End
1986-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
12
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Solberg Jr, L A; Tefferi, A; Oles, K J et al. (1997) The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 99:174-80
Danton, M C; Zaleski, A; Nichols, W L et al. (1994) Monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa inhibit adhesion of platelets to purified solid-phase von Willebrand factor. J Lab Clin Med 124:274-82
Machovich, R; Owen, W G (1993) Facilitation of plasminogen activation by a plasmin substrate containing a lysyl residue. Thromb Haemost 70:864-6
Zoldhelyi, P; Chesebro, J H; Owen, W G (1993) Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. Proc Natl Acad Sci U S A 90:1819-23
Lollar, P; Fay, P J; Fass, D N (1993) Factor VIII and factor VIIIa. Methods Enzymol 222:128-43
Machovich, R; Litwiller, R D; Owen, W G (1992) Requirement of zymogen modification for activation of porcine plasminogen. Biochemistry 31:11558-61
Nuttall, G A; Murray, M J; Bowie, E J (1991) Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology 74:138-45
Nesheim, M; Pittman, D D; Giles, A R et al. (1991) The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 266:17815-20
Precup, J W; Kline, B C; Fass, D N (1991) A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood 77:1929-36
Stone, S R; Schmitz, T; Henriksen, R A et al. (1991) Interaction of hirudin with the dysthrombins Quick I and II. Biochemistry 30:6392-7

Showing the most recent 10 out of 58 publications